tbuckley/cabot-search huggingface dataset:
SAT0422 Shoulder periarthritis in the hospital emergency department: Comparison between conventional and ultrasound-guided corticosteroids injection in terms of new visits and further follow up
Authors: C.A. Guillen Astete, M. Ahijon Lana, C. Medina Quiñones, C. Redondo, J.F. Borja Serrati, M. Prieto Morales
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Musculoskeletal conditions have an enormous impact worldwide reaching up to 17-18% of all main complains in an emergency department (ED). About 7% of all those complains are related to shoulder non-traumatic issues and most of them due to rotator cuff pathology which is also the most prevalent cause of re-visits to ED within a month in our local experience. The corticosteroid injection has been widely used to solve acute rotator cuff tendinitis or bursitis. Many studies have compared the ultrasound guided injection (UGI) versus the blind (physical examination-guided) injection (BI) of corticosteroids and their results are not conclusive. No studies have been conducted to analyze the save of sanitary resources. <h3>Objectives</h3> To evaluate the effectiveness of both techniques in terms of reduction of new ED visits and further need of specialized or primary care follow up. <h3>Methods</h3> A retrospective observational study was performed including patients over 16 years old, who visit our ED for the first time due to a shoulder periarthritis between 2008 and 2011. All of them had to have been formerly diagnosed by means of an ultrasound study and naive to steroids local injection. Cases were classified according to the US diagnosis and the type of procedure performed. For statistical analysis we used T-student or Chi-square test where appropriate. <h3>Results</h3> One hundred and twenty eight ED medical files were analyzed (96 BI, 32 UGI). Age and sex of both groups were comparable. Supraspinatus and subscapularis tendinosis proportions were similar in both groups as also subacromial bursitis. UGI Patients presented again fewer times to ED after the procedure, required fewer subsequent injections and less further follow up, although this last difference was not statistically significant. (See table). <h3>Conclusions</h3> Although the aim of this study was to observe the effect of two techniques in an homogenous group of cuff rotator pathology, several factors could have conditioned the decision between BI and UGI. Probably UGI was performed in complex cases (uncertain access, anticoagulated patients, and higher symptoms intensity). Even considering that fact, UGI reduced significantly the number of subsequent visits to the ED, the need for further steroids injections and showed a tendency to reduce the need of specialized follow up, thus we consider that UGI must be the technique of choice when its application is feasible. <h3>Disclosure of Interest</h3> None Declared
Bone Lymphoma
Authors: PAUL J. ROACH, MILOS J. JANICEK, WILLIAM D. KAPLAN
Journal: Clinical Nuclear Medicine (1996)

Assessment of response to therapy in patients with lymphoma involving bone can be difficult. Of the scintigraphic techniques available, Tl-201 may be the most ideal radiopharmaceutical because it reflects tumor burden more accurately than either Tc-99m MDP or Ga-67 citrate. We compared serial Tl-201 and Ga-67 citrate scintigraphs (24 studies, 12 pairs) in assessing the response to therapy in three patients with non-Hodgkin's lymphoma involving bone. In two patients who demonstrated a complete remission, uptake of Tl-201 diminished more rapidly and returned to normal earlier than did Ga-67 citrate. Tl-201 did not show tumor recurrence in the one patient with lesions shown to be Tl-201 negative at baseline. Serial studies using Tl-201 may be superior to Ga-67 citrate in the evaluation of lymphoma involving bone provided that Tl-201 avidity is demonstrated on baseline studies.
174 A SCORE PREDICTING SURVIVAL AFTER RETRANSPLANTATION FOR HEPATITIS C VIRUS CIRRHOSIS
Authors: A. Andres, E. Gerstel, C. Combescure, S. Asthana, S. Merani, T. Berney, P. Morel, N. Kneteman, G. Mentha, C. Toso
Journal: Journal of Hepatology (2012)
SP0003 Societal costs of RA - data from swedish national registers
Authors: M. Neovius
Journal: Annals of the Rheumatic Diseases (2012)

Health care organisations, pricing and reimbursement agencies, and the pharmaceutical industry all have interest in the economic burden of diseases, and how intervention can impact the cost trajectory. For the rheumatology field, this has attracted much interest after the introduction of the efficacious but expensive biologic therapies. Historically, economic costs related to a disease have generally been collected using questionnaires in samples of limited size. Non-response as well as recall bias may cause problems using such designs. Study cost may also become an issue if the sample size is to be expanded and/or efforts made to minimise non-response. Furthermore, attribution of costs to the disease is also difficult and risks becoming arbitrary. The aim of this presentation is to describe the potential and pitfalls of register-based estimation of costs associated with RA. This description will be exemplified by use of nationwide Swedish clinical quality registers for RA (the Swedish Rheumatology Register and the Swedish Biologics Register ARTIS), and how these can be linked to other national data sources on health care utilisation, drug dispensation, and productivity losses (sick leave and disability pension). Examples will be given for the prevalent cohort of patients with RA in Sweden (n$≈ $50,000), as well as incident patient cohorts (incident in terms of their RA disease or certain treatment exposures). The distribution of total costs across dispensed drugs (biologic/non-biologic), inpatient and outpatient care utilisation, sick leave and disability pension will be described from a register-perspective, as will the challenges posed by non-normal cost distributions. The importance of subgroup analyses, allowed for by the large sample size, will also be illustrated. Furthermore, an alternative to arbitrary attribution of costs to RA will be presented using individual-level matched comparators from the general population. This alternative is an empirical approach to the issue of which costs that are to be deemed as RA-related, and its strengths and weaknesses will be outlined. <h3>Disclosure of Interest</h3> None Declared
THE DETERMINANT FACTOR OF ANGIOSCOPIC YELLOW PLAQUE: EX VIVO COMPARISON OF ANGIOSCOPY AND HISTOPATHOLOGY
Authors: Masahiko Shibuya, Kenichi Fujii, Hiroyuki Hao, Takahiro Imanaka, Ten Saita, Masashi Fukunaga, Kojiro Miki, Hiroto Tamaru, Tetsuo Horimatsu, Machiko Nishimura, Akinori Sumiyoshi, Seiichi Hirota, Tohru Masuyama, Masaharu Ishihara
Journal: Journal of the American College of Cardiology (2015)
6The DNA helicase Mcm2 is required for cardiac looping
Authors: T Casar Tena, T Blaette, M Philipp
Journal: Cardiovascular Research (2014)

Purpose: The morphology and positioning of the heart greatly depends on the establishment of a left-right axis early during embryogenesis. A failure in symmetry breaking may result in heterotaxy, a condition with seemingly random arrangement of inner organs. Some of the most serious complications in these patients are severe congenital heart defects. We have used a systems biology approach to identify new factors guiding asymmetry development and with such proper cardiogenesis. Methods: We have applied phosphorylation-sensitive mass spectrometry to a zebrafish model of left-right asymmetry development. With this approach we identified minichromosome maintenance protein 2 (Mcm2) as a potential regulator of early heart development. Mcm2 is expressed in all dividing cells and was described as the unwinding helicase during DNA replication. Using an antisense morpholino oligonucleotides (MO)-based knockdown approach we have studied the impact of Mcm2 on laterality and heart development in zebrafish. Results: MO-mediated knockdown of Mcm2 produced randomization of cardiac looping as well as pancreas localization indicating a role of Mcm2 in asymmetry development. This hypothesis was strengthened by the aberrant expression of southpaw, a nodal related gene. Southpaw is normally expressed in the left lateral plate mesoderm. Mcm2 morphants, however, displayed randomization of this lateralization gene. Furthermore, we found that Mcm2 is expressed and functions in the organ of laterality, where it appears to regulate cilia formation. Conclusions: We have identified Mcm2 as a novel modulator of left-right asymmetry development.
THU0415 An Audit of Acute Side Effect Profile of Zolendronic Acid, Innovator Versus Generic Preparation
Authors: A. Kakar, A. Gogia, S. P. Byotra
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Zolendronic acid infusion is indicated in treatment and prevention of glucocorticoid induced osteoporosis, post-menopausal and male osteoporosis. The infusion is considered safe and well tolerated an even for domiciliary treatment. <h3>Objectives</h3> To study acute side effect profile of infusion of Zoledronic Acid (original) versus generic in acute setting <h3>Methods</h3> Retrospective data of 222 patients who were prescribed Zoledronic Acid (innovator or generic) over a 3 year period were analyzed to review the acute side effect profile. The 222 patieints laboratory values for serum calcium, creatinine and alkaline phsophatase were found to be normal in all patients. The infusion time varied between 15-30 minutes. A total of 154 (69.37%) patients received Zoledronic Acid (innovator) infusion and the 68 patients received generic Zoledronic acid infusion. Reinfusion was done in 78 subjects in subsequent year. <h3>Results</h3> The common indications of using the infusion were rheumatoid arthritis 58%, lupus 24%, systemic sclerosis 5.4%, other 12.6%. The common side effects in both groups were musculoskeletal followed by nervous system and gastrointestinal. Cardiac and renal were rare. 30% of the patient's with rheumatoid experienced increasing joint pains after the infusion which lasted for maximum 48 hours. Fever was seen in 44% in the innovator group vs 56% in generic group (p=0.0001). Fever had flu like presentation and usually settled with oral paracetamol. High grade fever (38°C) was less common and was seen in 6.5% in innovator group and 20.6% in generic group (p=0.002). Bony pains, myalgia, arthralgia and back ache were seen more in generic group, however, only arthralgia was statistically significant (p=0.022). Gastrointestinal systems were seen in 29.8% in innovator and 35.3% in generic. Parasthesias were commonest nervous system complaints seen in both the groups but was not statistically significant (p=0.102). There was one patient who developed renal failure in both the groups. Accelerated hypertension was seen in 1 patient in innovator group and atrial fibrillation was seen in generic group. Reinfusion was associated with 30% lesser side effects as compared to first infusion. <h3>Conclusions</h3> The side effect profile was more common in generic (55.88%) than the innovator group (35.06%). As Rheumatoid patients had transient increase in joint pains after infusion they should be counseled for this. Musculoskeletal and GI symptoms are most common after infusion, we would recommend Paracetamol and anti-emetic agents to be added empirically for 48 hours of therapy. <h3>Acknowledgements</h3> none <h3>Disclosure of Interest</h3> None Declared
The Early Diagnosis of Phlebothrombosis
Authors: William R. Moses
Journal: New England Journal of Medicine (1946)

NOTHING so captivates the medical mind as the prevention of catastrophe by a simple method. Thus may be explained the rapidly increasing popularity of proximal ligation of thrombosed veins for the prevention of pulmonary embolism. Indeed, there must be few surgeons, who have not witnessed the shockingly sudden transition of a happy convalescent into a patient rapidly dying from this totally unexpected disaster. Nor is the picture of so-called "thromboembolism"1 infrequent. Neumann2 in a study of 165 random cadavers, found that 65 per cent of them demonstrated ante-mortem venous thromboses of the lower leg, 52 per cent of which were . . .
EFFICACY AND SAFETY OF NOVEL ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE: A META-ANALYSIS OF PHASE III CLINICAL TRIALS
Authors: Gianluigi Savarese, Giuseppe M.C. Rosano, John McMurray, Robert Giugliano, Bruno Trimarco, Giovanni G. Camici, Pasquale Perrone-Filardi
Journal: Journal of the American College of Cardiology (2015)
AB0909 Prevalence of cardiovascular risk factors in patients with espondiloarthritis in manises’ hospital rheumatology unit:
Authors: S. Muñoz Gil, A. Conesa Mateos, T. Mut Dόlera, P. Muñoz Mira
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> Describe the prevalence of cardio and brainvascular diseases as well as the risk factors in patients with inflammatory espondiloarthritis in our health area. <h3>Methods</h3> Transversal study of a cohort of patients diagnosed of espondiloarthritis(AS:modified New York criteria;Psoriasic arthritis: ESSG criteria) in Manises’ Hospital Rheumatology Unit,from the 1st of July 2011 until the 15th of November 2011.We registered different variables as socio-demographic,disease,cardiovascular risk factors,physical examination and serum levels.The SPSS Statistic version 20 was used for calculating statistics. <h3>Results</h3> 60 patients were included(41 men;19 women)with an average age of 47±12 years old.39 patients were diagnosed of AS while 21 were diagnosed of PsoA.They presented axial symptomes in 39, articular in 19 and 2 patients with both localizations affected.The average evolution time of the disease was of 8.8±6 years.55% of the patients were HLA-B27+,10% had suffered from at least one episode of uveitis,28% cutaneous and or nail psoriasis and 7% had frequent episodes of diarrhea.The C Reactive Protein average levels were 5.6±8.43 mg/dl while ESR levels were of 9.5±9.84.According to therapy,1 patient wasn’t taking medication,10 patients were taking NSAIDs(including COX-2)as monotherapy,24 patients had classic DMARDs and 25 had anti-TNFalpha.In the following table the prevalences of the main cardiovascular risk factors of the patients from our cohort are shown.The average BMI was of 28.1 + 4, presenting indexes of overweight or obesity in 80% of the patients.The mean abdominal perimeter was of 93.1 + 14, being in 30% of men &gt;102 cm and in 60% of the women &gt;88 cm. Table of the prevalences of the main cardiovascular risk factors of the patients from our cohort: <h3>Conclusions</h3> In patients with chronic inflammatory espondiloarthropathies in our health area there is a high prevalence of classic cardiovascular risk factors, specially sedentarism and overweight. However, they show a low prevalence of cardiovascular events, probably due to the mean age of our patients. Studying the prevalences of the cardiovascular risk factors in patients with espondiloarthritis, which include antropometric, blood pressure and lab measurements, allow us to determine the real risk prevalence as well as to define new strategies of cardiovascular prevention. <h3>Disclosure of Interest</h3> None Declared
Performance of additional colonoscopies and yield of neoplasms within 3 years after screening colonoscopy: a historical cohort study
Authors: C. Stock, M. Hoffmeister, B. Birkner, H. Brenner
Journal: Endoscopy (2013)

<b>Background and study aims:</b> After screening colonoscopy, additional colonoscopies may be required for adenoma surveillance or diagnostic reasons. The aim of the present study was to explore their utilization and findings in routine practice. <b>Patients and methods:</b> The study comprised an historical cohort of individuals participating in colonoscopy screening in 2006. Utilization and yield of neoplasms of additional colonoscopies performed in these individuals by the same physician ( < 6 months and 6 – 36 months after screening) between 2006 and 2009 were assessed using data of a colonoscopy quality assurance program in Bavaria, Germany. Screening including polypectomy, and short-term follow-up colonoscopy was assumed to have been completed within ≤ 6 months. Multivariate logistic regression was used to identify predictors of additional colonoscopy and advanced neoplasms (high risk adenoma or colorectal cancer [CRC]) among those with additional colonoscopy during the period of 6 – 36 months after screening. <b>Results:</b> A total of 51 301 individuals undergoing screening colonoscopy were included. Of these, 10.1 % (95 % confidence interval [CI] 9.8 % – 10.3 %) had an additional colonoscopy performed by the same physician between 6 and 36 months after screening. The percentages of those with additional colonoscopy were 5.7 % (95 %CI 5.5 % – 5.9 %), 18.6 % (95 %CI 17.8 % – 19.4 %), and 33.7 % (95 %CI 32.2 % – 35.2 %) after negative screening, low risk adenoma at screening, and high risk adenoma at screening, respectively. The overall findings were negative colonoscopy, low risk adenoma, high risk adenoma, and CRC in 68.6 % (95 %CI 67.3 % – 69.8 %), 24.1 % (95 %CI 23.0 % – 25.3 %), 6.7 % (95 %CI 6.0 % – 7.4 %), and 0.6 % (95 %CI 0.4 % – 0.8 %), respectively. Younger age, male sex, screen-detected adenomas, inflammatory bowel disease, and early repeat colonoscopy within 6 months were predictors of additional colonoscopy. Older age, male sex, screen-detected adenomas, and surveillance indications were associated with increased risk of advanced neoplasms at post-screening colonoscopy. <b>Conclusion:</b> The results indicate frequent utilization of additional colonoscopies along with substantial adenoma yield in the first 3 years after screening colonoscopy.
PMO-224 NF-κB2 deletion protects murine colon against DSS-induced colitis and this is associated with reduced expression of TNF-α and IL14
Authors: A Hanedi, M D Burkitt, C A Duckworth, R Dimaline, J H Caamano, D M Pritchard
Journal: Gut (2012)

<h3>Introduction</h3> The Nuclear Factor kappa B (NFκB) family of five transcription factors signals via two pathways (classical and alternative). Classical pathway NFκB signalling has previously been implicated in the pathogenesis of inflammatory bowel diseases (IBD). However, the role of alternative NFκB pathway activation in the development of intestinal inflammation has not previously been investigated. <h3>Aims</h3> To investigate the susceptibility of mice deficient in two individual NFκB family members to DSS-induced colitis and the associated molecular changes. <h3>Methods</h3> Colitis was induced in adult male NFκB1-null and NFκB2-null mice and their wild-type (C57BL/6) counterparts by oral 2% DSS administration for 5 days (n=10 per group). Weight loss and Disease Activity Index (DAI) were evaluated daily. Animals were euthanased on day 6 and histological colitis severity was evaluated in H/E stained colonic sections. The colonic expression of 6 key pro-inflammatory cytokines (TNF-α, IL-1β, INF-γ, IL-6 and IL-14) was assessed by real time PCR (n=4 per group). Statistical comparisons were mostly performed by ANOVA with Bonferroni post-hoc tests, but the Kruskal–Wallis with Dunn9s multiple comparison test was used to analyse DAI and histological scores. <h3>Results</h3> After oral administration of 2% DSS, NFκB1-null mice showed significantly more loss of body weight whereas NFκB2-null mice showed significantly less loss of body weight on days 5 and 6 compared to wild-type mice. DAI was also significantly higher in NFκB1-null mice and significantly lower in NFκB2-null mice compared to C57BL/6 mice. In agreement with these clinical findings, histological assessment of DSS treated animals confirmed a severely damaged and inflamed distal colon in C57BL/6 and NFκB1-null mice and minimal histological damage and significantly lower inflammation scores in NFκB2-null mice. The expression of IL-6 mRNA was significantly increased in DSS-treated NFκB1-null colon and the expressions of TNF-α and IL-14 mRNAs were significantly reduced in DSS-treated NFκB2-null colon. <h3>Conclusion</h3> Disruption of the classical NFκB signalling pathway by deleting NFκB1 exacerbates colonic inflammation and tissue damage following DSS administration which may be partially mediated by IL-6. This suggests that classical NFκB pathway inhibitors may be paradoxically harmful in IBD. However, disruption of the alternative pathway by deleting NFκB2 protected murine colon from developing inflammation and this was associated with reduced expression of TNF-α and IL-14. Pharmacological inhibition of the NFκB2 signalling pathway may therefore be a promising novel therapeutic strategy for IBD. <h3>Competing interests</h3> None declared.
Incidental cystic lesions of the pancreas found on Endoscopic ultrasound (EUS)
Authors: P Nguyen, A Le
Journal: Endoscopy (2011)

Background: Cystic lesions of the pancreas are increasingly found with the widespread use of cross-sectional imaging studies such as CT and MRI. Incidental cysts are seen in 0.7% of the American population without known pancreatic disease. No prior EUS studies have reported the detection rate of incidental pancreatic cysts. Purpose: Our aim was to find the incidental detection rate of pancreatic cysts on upper EUS exams. Methods: We retrospectively reviewed 785 patients who underwent upper EUS exams for non-pancreatic indications (2/06–7/10). The various indications for the EUS exams included gastric or duodenal lesions (n=222), biliary or liver indications (n=209), periluminal masses and nodes (n=112), abdominal pain (n=109), esophageal masses (n=93), and miscellaneous indications (n=40). The mean age of the patients was 63 (range 17–94), 332M/453 F. Results: Of the 785 patients, incidental pancreatic cysts were found in 21.8% (n=171). Of the 171 patients, 63.95% had a single cyst. The mean largest cyst dimension was 5.5mm (range 1–55mm). Of the 171 patients with pancreatic cysts, 11% (n=18) had follow-up EUS exams (from 1–14 months after the initial EUS exam). In 61% (n=11) of those who had EUS follow-up exams, the cysts were unchanged or smaller. The mean age was 70 for patients with incidental cysts and 61 for those without. Conclusions: Pancreatic cysts were found incidentally in 22% of patients who underwent upper EUS exams for non-pancreatic indications. On EUS follow-up exams, the incidentally found pancreatic cysts were smaller or remained unchanged in 61.1% and were no longer present in 38.9%. Patients with incidentally found pancreatic cysts were significantly older than those without (p<0.01).
P834 NON-INVASIVE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
Authors: R. Gallego-Durán, P. Cerro-Salido, M.J. Pareja, I. Ranchal, M.C. Rico, L. Rojas, R. Aznar, E. Bugianesi, J. Crespo, M.T. Arias-Loste, J. Abad, S. Soto, R. Aparcero, I. Moreno, J.L. Calleja, O. Lo Iacono, R. Andrade, E. Gómez-González, M. Romero-Gómez
Journal: Journal of Hepatology (2014)